Millions in US use unapproved GLP-1sβand use them in unapproved ways
Cost and access barriers are pushing people to modified use and unapproved versions.
Cost and access barriers are pushing people to modified use and unapproved versions.
9 women share their GLP-1 side effects. Watch the full episode at CNN.com/BodyLanguage.
Two doctors explain the big mistakes that cause GLP-1 side effects. Watch the full episode at CNN.com/BodyLanguage.
The risk appears small and data is mixed, but FDA wants patients to be aware.
The US Food and Drug Administration says Ozempic, Wegovy, and other weight-loss drugs must have labels about the condition, known as NAION.
The agency has found evidence of a potential increased risk of a rare eye condition linked to the use of GLP-1 drugs used for weight management and diabetes.
Novonesis is exploring whether gut health supplements could benefit patients taking GLP-1 weight-loss drugs, opening up a potentially lucrative new market.
Rapid weight loss can trigger hair loss, heart complications and vitamin deficiencies if nutrient needs go unmet, health experts have warned.
Rapid weight loss can trigger hair loss, heart complications and vitamin deficiencies if nutrient needs go unmet, health experts have warned.
The medication, traditionally used for diabetes, has been approved for weight management and cardiovascular concerns.
Wegovyβs GLP-1 weight loss tablet has been approved in Australia for the first time, expected to lead to a surge in demand for the sought-after peptide which could hit the market by the end of this year.
Wegovyβs GLP-1 weight loss tablet has been approved in Australia for the first time, expected to lead to a surge in demand for the sought-after peptide which could hit the market by the end of this year.
Since CNBC highlighted the stock's attractive valuation in August, shares have gained around 20%. Why we expect more upside ahead.
Weight-loss drugs like Ozempic and Wegovy are becoming increasingly popular among Americans, but their impact could extend well beyond personal health. New research suggests that GLP-1s could influence everything from hiring decisions to workplace productivity. Meanwhile, employers are facing questions about whether covering these expensive medications is worth the cost, and whether the potential benefits for their workforce justify the investment.
As GLP-1 use reaches new highs, more employers are grappling with whether the benefits of covering these medications justify their high costs.
Coverage of GLP-1 drugs for weight loss is being dropped by many employer-sponsored healthcare plans as premiums soar, though workers have some new options.
As the weight-loss drugs become more common, some runners find the side-effects challenging. Hereβs what experts say